Article List

WPRIM Management System> DCMS> Diabetes & Metabolism Journal> 2015> 39> 5

Volume: 39 Issue: 5

1. Erratum: Figure Correction: Probiotics as Complementary Treatment for Metabolic Disorders.	Page:448—449
2. Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).	Page:446—447
3. Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).	Page:444—445
4. Identification of Two Cases of Ciliopathy-Associated Diabetes and Their Mutation Analysis Using Whole Exome Sequencing.	Page:439—443
5. Relationship between Biological Markers, Metabolic Components, Lifestyles, and Impaired Fasting Glucose in Male Workers.	Page:434—438
6. The Preventive Effects of 8 Weeks of Resistance Training on Glucose Tolerance and Muscle Fiber Type Composition in Zucker Rats.	Page:424—433
7. Serum Total Bilirubin Levels Provide Additive Risk Information over the Framingham Risk Score for Identifying Asymptomatic Diabetic Patients at Higher Risk for Coronary Artery Stenosis.	Page:414—423
8. Increased Epicardial Adipose Tissue Thickness in Type 2 Diabetes Mellitus and Obesity.	Page:405—413
9. The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients: A Nationwide Cross-Sectional Study in Thailand.	Page:395—404
10. Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea.	Page:387—394
11. Role of Bilirubin in Diabetic Vascular Complications: Can Bilirubin Predict More than Just Liver Disease?.	Page:384—386
12. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.	Page:373—383
13. Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity.	Page:363—372
14. Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia.	Page:353—362